SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
4.580
+0.480 (11.71%)
At close: Mar 11, 2026, 4:00 PM EDT
4.640
+0.060 (1.31%)
After-hours: Mar 11, 2026, 7:55 PM EDT
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
233.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Compugen | 72.76M |
| Protalix BioTherapeutics | 61.84M |
| MediWound | 16.96M |
| Surrozen | 3.60M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 1.57M |
SABS News
- 1 day ago - SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - GlobeNewsWire
- 2 days ago - SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 9 days ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - GlobeNewsWire
- 2 months ago - SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D - GlobeNewsWire
- 3 months ago - SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D - GlobeNewsWire
- 3 months ago - SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - GlobeNewsWire